SIBO is an overgrowth of bacteria, archaea or fungi in the small intestine, diagnosed mainly by breath testing and treated with non-absorbed antibiotics such as rifaximin plus prokinetics. Relapse exceeds 50% within six months when the underlying motility or structural cause is not fixed, and the biofilm hypothesis is the leading explanation for treatment failures. Much of the biofilm evidence is indirect, so this entry stays speculative.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
What is SIBO?
An abnormal increase in bacteria, archaea or fungi in the small intestine, which is normally kept fairly sterile by stomach acid and cleansing motility waves. The organisms ferment carbohydrates and produce gas, bloating, diarrhea or constipation.
How is SIBO diagnosed?
Mainly by breath tests measuring hydrogen, methane and increasingly hydrogen sulfide after a lactulose or glucose drink. Duodenal aspirate culture is the gold standard but is rarely performed.
Why does SIBO keep coming back?
Relapse exceeds 50% at six months if the root cause, such as a motility disorder, low stomach acid, adhesions or a drug effect, is not corrected. Biofilms and intracellular hiding are proposed reasons antimicrobials alone fail.
Is SIBO linked to IBS?
Possibly. The body cites work suggesting up to 60% of IBS cases may be SIBO-related, and breath testing is increasingly used in functional gastroenterology.
What would change this rating?
Direct visualization of small-bowel biofilms in humans and controlled trials of biofilm-disruption protocols. Current biofilm evidence is mostly indirect, from treatment-response patterns, animal models and in-vitro work.
Comprehensive coverage of small intestinal bacterial overgrowth (SIBO), fungal overgrowth (SIFO), archaeal overgrowth (SIMO), biofilm-associated gut dysfunction, and disruption protocols. SIBO represents one of the most common and misdiagnosed conditions in functional gastroenterology — and biofilms are a primary reason standard antimicrobial protocols fail.
02Overview
Small intestinal bacterial overgrowth (SIBO) is defined as an increase in the total number of bacteria in the small intestine, or a change in the composition of those bacteria, beyond what is normally found in the small bowel. Unlike the colon — which is designed to house massive bacterial loads — the small intestine typically maintains relatively low bacterial counts through:
- Migrating motor complexes (MMC) — housekeeping waves that sweep contents toward the colon
- Ileocecal valve — prevents retrograde colonic bacterial migration
- Gastric acid — bactericidal for most ingested organisms
- Secretory IgA — immune surveillance at the mucosal surface
- Pancreatic enzymes — proteolytic environment unfavorable to many bacteria
When these defense mechanisms fail, bacteria (or fungi, archaea) can colonize the small intestine, fermenting carbohydrates and producing gas, toxins, and inflammation. Critically, many SIBO-associated bacteria exist within biofilm communities, making them 100-1000x more resistant to antimicrobial therapy than their planktonic counterparts.
SIBO vs. SIFO vs. SIMO
| Condition | Organism Type | Prevalence | Biofilm Involvement |
|---|---|---|---|
| SIBO | Bacteria (coliforms, streptococci, anaerobes) | Most common | High — polymicrobial biofilms |
| SIBO-C | Methanogenic archaea (methane-dominant) | Common | Moderate — archaeal biofilms |
| SIFO | Fungal species (Candida, Malassezia) | Underrecognized | High — Candida biofilms |
| SIMO | Methanogens, occasionally Desulfovibrio | Less studied | Moderate |
Swipe table →
03The Biofilm Connection in SIBO
Why Standard SIBO Treatment Fails
The standard SIBO treatment paradigm — antimicrobial herbs or antibiotics + prokinetic + dietary modification — fails a significant proportion of patients. The biofilm hypothesis provides a mechanistic explanation:
- Pre-existing biofilm communities in the small intestine are not eliminated by standard antimicrobials at achievable intraluminal concentrations
- Persister cells within biofilms survive treatment and repopulate after discontinuation
- Intracellular pathogens (Listeria, Yersinia, mycobacteria) hide within enterocytes, invisible to both immune system and most antimicrobials
- Fungal-bacterial polymicrobial biofilms (Candida + bacteria) provide cross-protection
Biofilm Formation in the Gut
The gut mucosa is an ideal biofilm environment:
- Mucus layer — is attachment substrate for biofilm formation
- Peristalsis — low-amplitude, non-disruptive to established biofilms
- Nutrient availability — constant food supply for embedded organisms
- Immune evasion — biofilm matrix shields bacteria from IgA, macrophages, neutrophils
Evidence for Biofilms in SIBO
| Study | Finding | PMID |
|---|---|---|
| Analysis of mucosal biopsies in IBS patients | Biofilm presence correlated with symptom severity and treatment resistance | 33177128 |
| Duodenal aspirate studies | SIBO patients show bacterial clusters consistent with biofilm morphology | 32090409 |
| Animal models of SIBO | Antibiotic treatment clears planktonic bacteria but biofilms persist and repopulate | 28978838 |
| Candida biofilms in SIBO | Fungal presence in small bowel associated with treatment-refractory cases | 30395373 |
Swipe table →
04Root Causes: Why the MMC Stops
Before treating SIBO, identifying and addressing the underlying cause is essential. Recurrent SIBO is almost always secondary to an underlying predisposing factor.
Structural/Mechanical Causes
| Cause | Mechanism | Diagnosis |
|---|---|---|
| Postsurgical blind loops | Stasis in afferent limb | Small bowel follow-through |
| Small bowel adhesions | Obstruction/stasis | CT enterography |
| Fistulae | Diverticular-like pouches | Capsule endoscopy |
| Ileocecal valve insufficiency | Allows colonic backflow | Breath test response pattern |
Swipe table →
Motility Disorders
| Cause | Mechanism | Key Feature |
|---|---|---|
| Neuropathy (diabetes, scleroderma) | Damaged autonomic nerves | Chronic, relapsing |
| Post-infectious dysmotility | MMC disruption after gastroenteritis | Onset after food poisoning |
| Medication-induced | Opiates, anticholinergics, GLP-1 agonists | Drug history |
| Hypochlorhydria | Loss of gastric acid barrier | Often iatrogenic (PPI use) |
Swipe table →
Immune Dysfunction
- IgA deficiency — loss of mucosal immune surveillance
- Common variable immunodeficiency (CVID) — impaired bacterial clearance
- AIDS — loss of immune competence
Dietary Drivers
- High fermentable carbohydrate diet — feeds bacterial overgrowth
- SIBO-promoting foods — FODMAPs, resistant starch, alcohol
- Western diet — dysbiosis-promoting, low in prebiotics that support butyrate producers
05Classification by Breath Test Findings
Hydrogen-Dominant SIBO
- Organisms: Streptococcus, Escherichia coli, Staphylococcus, Enterococcus
- Mechanism: Bacterial fermentation of carbohydrates → hydrogen gas
- Symptoms: Bloating, diarrhea, flatulence, malabsorption
- Treatment: Elemental diet + rifaximin (non-absorbed rifamycin)
- Methane cutpoint: Typically CH₄ <10 ppm rise over baseline
Methane-Dominant SIBO (IMO — Intestinal Methanogenic Overgrowth)
- Organisms: Methanobrevibacter smithii, Methanosphaera stadtmanae
- Mechanism: Archaeal methanogenesis from H₂ + CO₂ → CH₄
- Symptoms: Severe constipation, bloating, brain fog, weight gain
- Key: Methane slows intestinal transit (prokinetic effect of CH₄)
- Treatment: Rifaximin + neomycin or rifaximin + metronidazole; biofilm disruption critical
- Methane cutpoint: CH₄ ≥10 ppm or >3 ppm rise from baseline
Hydrogen Sulfide SIBO
- Organisms: Desulfovibrio, Bilophila wadsworthia, sulfate-reducing bacteria
- Mechanism: Sulfate reduction → H₂S gas
- Symptoms: Diarrhea, IBS-D, foul sulfurous flatulence, food protein sensitivity
- Testing: Trio Smart breath test or flatone testing
- Treatment: Bismuth subsalicylate, molybdenum cofactor support
06Uses
Biofilm disruption should precede or accompany antimicrobial treatment. Attempting to eradicate SIBO with antimicrobials alone while biofilms are intact has poor long-term success.
Phase 1: Biofilm Disruption (Weeks 1-2)
Enzymatic Disruption
| Agent | Mechanism | Evidence |
|---|---|---|
| N-acetylcysteine (NAC) | Mucolytic, disulfide bond reduction in EPS matrix | Strong — 8-study systematic review (European Review, 2021) |
| Serrapeptase | Proteolytic enzyme, digests fibrin barrier | Moderate — better in combination |
| Nattokinase | Fibrinolytic, plasmin activation | Preliminary — theoretical benefit |
| Lumbrokinase | Fibrinolytic, more potent than nattokinase | Preliminary |
Swipe table →
Chelation and Mineral-Binding Agents
| Agent | Notes |
|---|---|
| EDTA | Binds divalent cations (Ca²⁺, Mg²⁺) required for biofilm adhesion |
| Sodium EDTA (topical for sinus) | For nasal/sinus biofilm component |
Swipe table →
Herbal Biofilm Disruptors
| Agent | Mechanism |
|---|---|
| Berberine | Inhibits AI-2 quorum sensing, antifungal |
| Garlic (allicin) | Allicin disrupts disulfide bonds in EPS matrix |
| Grapefruit seed extract | Antifungal + anti-biofilm |
| Curcumin | Anti-inflammatory + quorum sensing inhibition |
| Oregano oil | Antimicrobial + disrupts fungal biofilms |
Swipe table →
Phase 2: Antimicrobial Treatment (Weeks 2-4)
Pharmaceutical Options
| Agent | Notes |
|---|---|
| Rifaximin | Non-absorbed; first-line for hydrogen SIBO |
| Rifaximin + Neomycin | Gold standard for IMO |
| Rifaximin + Metronidazole | Alternative for IMO |
| Ciprofloxacin | Culture-directed if available |
| Metronidazole | Better for anaerobes |
Swipe table →
Herbal Antimicrobials (SIBO-Conscious)
| Formula | Notes |
|---|---|
| Candibactin-AR (Metagenics) | Berberine + thyme + oregano |
| Berberine + Allicin | For combined bacterial/fungal |
| FC Cidal (Designs for Health) | Antimicrobial botanical blend |
| Biota-Cid | For methane-dominant |
Swipe table →
Phase 3: Prokinetic and Gut Healing (Ongoing)
Restoring MMC function is critical to prevent rapid repopulation:
| Agent | Mechanism |
|---|---|
| Ginger | Prokinetic, supports MMC |
| Artichoke leaf extract | |
| Low-dose naltrexone (LDN) | |
| Erythromycin (low-dose) | |
| Prucalopride |
Swipe table →
07The Elemental Diet Approach
The elemental diet provides complete nutrition in pre-digested liquid form, "starving" small bowel bacteria while maintaining patient nutrition. It is the most effective dietary intervention for SIBO but is demanding.
Uses
- Duration: 2-3 weeks of exclusive elemental diet
- Mechanism: Removes fermentable substrate from small bowel; bacteria are starved
- Efficacy: ~80% normalization of breath tests in published series
- Drawbacks: Unpalatable, expensive, requires medical supervision
Breaking the Elemental Diet
- Days 1-2: Introduce easily digestible foods (bone broth, steamed vegetables)
- Days 3-5: Add single protein sources
- Days 6-7: Gradual reintroduction of broader diet
- Immediately start prokinetic after completing elemental phase
08SIFO (Small Intestinal Fungal Overgrowth)
Fungal overgrowth is underrecognized as a cause of SIBO-refractory cases. Candida species can form robust biofilms on small bowel mucosa and are intrinsically resistant to many antifungals.
Risk Factors
- Antibiotic use (disrupts bacterial competition)
- PPI use (reduced gastric acid barrier)
- Diabetes (elevated glucose)
- Immunosuppression
- High-carbohydrate diet
09Dietary Considerations
SIBO-Promoting Foods to Avoid
| Category | Examples | Why Problematic |
|---|---|---|
| FODMAPs | Garlic, onion, wheat, legumes, dairy | Rapidly fermented → gas, osmotic effect |
| Resistant starch | Cooked-and-cooled potatoes, rice | Escapes small bowel digestion |
| Alcohol | Beer, wine | Feeds methanogens; direct mucosal toxicity |
| High glucose | Simple sugars, refined carbs | Bacterial fuel |
| Gluten | Wheat, barley, rye | May increase intestinal permeability |
Swipe table →
SIBO-Supportive Foods
| Category | Examples | Mechanism |
|---|---|---|
| Polyphenols | Berries, dark chocolate | Anti-inflammatory, anti-quorum sensing |
| Omega-3s | Fatty fish, flax | Anti-inflammatory, supports tight junctions |
| MCT oil | Coconut oil | Direct antifungal, rapid absorption |
| Bone broth | Long-cooked | Glutamine for gut lining, gelatin |
| Fermented dairy (low-lactose) | Kefir, aged cheese | Probiotic |
| Low-FODMAP vegetables | Zucchini, carrots, leafy greens | Fiber without excess fermentation |
Swipe table →
10The Gut-Sinus Axis
The respiratory and gastrointestinal tracts share a common mucosal immune system (MALT — mucosa-associated lymphoid tissue), and biofilm communities in one may influence the other:
- Chronic sinusitis is associated with SIBO in functional medicine observations
- Nasal microbiome dysbiosis can seed the gut via swallowed secretions
- SIBO treatment sometimes improves sinus symptoms via reduced systemic inflammation
- Sinus biofilms may act as a reservoir for bacteria that repopulate the gut
See Chronic Sinus and Gut Biofilms for detailed coverage.
11Diagnostic Approaches
Breath Testing
| Test | What It Measures | SIBO Cutoffs | Limitations |
|---|---|---|---|
| Trio Smart (lactulose) | H₂, CH₄, H₂S | H₂ ≥20 ppm rise ≤90 min; CH₄ ≥12 ppm; H₂S ≥2 ppm | Ventilation affects results |
| QuinTron (glucose or lactulose) | H₂, CH₄ | H₂ ≥12 ppm rise; CH₄ ≥10 ppm | Requires good oral hygiene |
| Tryptophan metabolism | Urine indican | Indirect | Poor specificity |
Swipe table →
Endoscopic Culture
- Gold standard but not routinely performed
- Quantitative duodenal/jejunal aspirate (≥10³ CFU/mL = positive)
- Allows organism identification and sensitivities
- Biofilm sampling requires specialized techniques
Organic Acid Testing (OAT)
- Urine metabolites from microbial metabolism
- D-arabinitol (Candida), HPHPA (Clostridia), Tartaric acid (yeast)
- Functional rather than diagnostic; useful for guiding treatment
12Practical Notes
Treatment Order
- Confirm diagnosis with breath test (or treat empirically if classic presentation)
- Identify and address root cause (motility disorder, hypochlorhydria, structural)
- Begin biofilm disruption 3-7 days before starting antimicrobials
- Antimicrobial phase (herbal or pharmaceutical)
- Prokinetic initiated day 1 of antimicrobial or immediately after
- Gut healing (L-glutamine, colostrum, zinc carnosine) after antimicrobial phase
- Dietary reintroduction over 2-4 weeks
- Long-term maintenance with prokinetic + dietary modifications
Duration and Relapse
- Most patients require 2-4 rounds of antimicrobial treatment
- Relapse rate without addressing root cause is high (>50% at 6 months)
- Prokinetic use should continue for 3-6 months minimum
- Addressing sleep, stress, and MMC function is critical for cure
When to Suspect Biofilm-Dominant SIBO
- Failed 2+ rounds of standard antimicrobial therapy
- Symptoms improve but never fully resolve
- Breath test normalizes but symptoms persist (may indicate fungal component)
- Known sinus or dental biofilm history
- History of prolonged antibiotic use
13Notes
- Evidence gaps: Direct visualization of gut biofilms in humans remains technically challenging; most evidence is indirect (treatment response patterns, animal models, in vitro studies)
- H₂S SIBO is the least studied and most difficult to treat; molybdenum cofactor supplementation (which supports sulfite oxidase) is theoretically helpful but understudied
- IMO vs. SIBO: The nomenclature is evolving; "IMO" (Intestinal Methanogenic Overgrowth) is now preferred to reflect that methanogens are archaea, not bacteria
- SIBO and IBS: Up to 60% of IBS cases may be SIBO-related (Pimentel et al.); breath testing is increasingly standard in functional GI practice
14Connections
15Sources
16Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.